Purpose of Review: This review aims to summarize the role of the interleukin-1 (IL-1) blocking agents in cardiovascular diseases, briefly describing the pathogenetic rationale and the most relevant clinical studies. Recent Findings: IL-1 is a pivotal cytokine of the innate immune system. Anti-IL-1 agents are currently used for the treatment of several autoimmune and autoinflammatory conditions. Recently, the role of IL-1 has also emerged in cardiovascular diseases. Indeed, two recent randomized controlled trials have shown that the IL-1 receptor antagonist anakinra is effective for the treatment of idiopathic recurrent pericarditis and the IL-1β blocking agent canakinumab is effective in reducing myocardial infarction in people at risk. Interestingly, interfering with IL-1 has proved to be also effective in other cardiovascular manifestations, such as myocarditis, arrhythmias, and heart failure. Summary: Blocking the IL-1 pathway is a possible new therapeutic strategy, potentially leading to innovative therapies in many acute and chronic cardiovascular diseases.
Use of Interleukin-1 Blockers in Pericardial and Cardiovascular Diseases / G. Emmi, M.L. Urban, M. Imazio, M. Gattorno, S. Maestroni, G. Lopalco, L. Cantarini, D. Prisco, A. Brucato. - In: CURRENT CARDIOLOGY REPORTS. - ISSN 1523-3782. - 20:8(2018), pp. 61.1-61.12.
|Titolo:||Use of Interleukin-1 Blockers in Pericardial and Cardiovascular Diseases|
|Parole Chiave:||Anakinra; Atherosclerosis; Canakinumab; Cardiovascular disease; Interleukin-1; Pericarditis; Cardiology and Cardiovascular Medicine|
|Settore Scientifico Disciplinare:||Settore MED/09 - Medicina Interna|
|Data di pubblicazione:||2018|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1007/s11886-018-1007-6|
|Appare nelle tipologie:||01 - Articolo su periodico|
File in questo prodotto:
|Emmi2018 IAEM_Article_UseOfInterleukin-1BlockersInPe.pdf||Publisher's version/PDF||Administrator Richiedi una copia|